What is multiple sclerosis? The autoimmune disease affecting 3 million people - ...
Platform disease-modifying therapies show no significant difference in relapse-independent progression among patients with ...
DelveInsight's 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline relapsing-remitting multiple ...
A lab study found that vitamin D and curcumin, especially when combined, altered immune responses in blood cells from people ...
DelveInsight’s ‘Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Relapsing-Remitting Multiple Sclerosis therapies in various ...
A study by the University of Eastern Finland found that quality of life in people with multiple sclerosis (MS) is strongly associated with walking performance and functional capacity. A major ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing ...
Background Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple ...
Stem cell therapy can safely slow progression of relapsing-remitting multiple sclerosis, finds study
Autologous hematopoietic stem cell transplantation, or aHSCT for short, is usually used to treat blood cancers, and involves harvesting stem cells from the person's own bone marrow or blood followed ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...
WALTHAM - Zenas BioPharma, Inc. ('Zenas' or the 'Company') (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results